Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age

Pediatric Infectious Disease Journal

Volumn 34, Issue 7, 2015, Pages 748-752

  Bradley, John S ^a   Puttagunta, Sailaja ^b   Rubino, Christopher M ^c   Blumer, Jeffrey L ^d   Dunne, Michael ^a   Sullivan, Janice E ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Durata Therapeutics   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d MEDICAL COLLEGE OF OHIO   (United States)

^e University of Louisville School of Medicine   (United States)

Author keywords

dalbavancin; pediatric; pharmacokinetics

Indexed keywords

DALBAVANCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ABDOMINAL PAIN; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION RATE CONSTANT; FEMALE; HUMAN; HYPOTENSION; ILEUS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RENAL CLEARANCE; RISK ASSESSMENT; SINGLE DRUG DOSE; SKIN INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; WOUND; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HOSPITAL PATIENT; INTRAVENOUS DRUG ADMINISTRATION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; MALE; TEICOPLANIN;

EID: 84938886414     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000646     Document Type: Article

References (10)

1. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005; 41: 1407-1415.
2. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370: 2169-2179.
3. Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004; 48: 137-143.
4. Jones RN, Sader HS, Flamm RK,. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013; 75: 304-307.
5. Malabarba A, Goldstein BP,. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005; 55 (suppl 2): ii15-20.
6. Chen AY, Zervos MJ, Vazquez JA,. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007; 61: 853-863.
7. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48: 940-945.
8. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005; 55 (suppl 2): ii25-30.
9. Marbury T, Dowell JA, Seltzer E, et al. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009; 49: 465-476.
10. Andes D, Craig WA,. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007; 51: 1633-1642.